SCHEMBL4130872

SCHEMBL4130872

CC(NC(=O)Nc1ccc2[nH]nc(N)c2c1)c1cccc(F)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 13/20 0.69
MTOR P42345 1/20 0.57
BAZ1A Q9NRL2 1/20 0.56
JAK2 O60674 2/20 0.50
JAK1 P23458 2/20 0.50
ULK1 O75385 1/20 0.50
ABL1 P00519 1/20 0.49
LCK P06239 1/20 0.49
FYN P06241 1/20 0.49
CSF1R P07333 1/20 0.49
LYN P07948 1/20 0.49
KIT P10721 1/20 0.49
SRC P12931 1/20 0.49
FLT1 P17948 1/20 0.49
FLT4 P35916 1/20 0.49
KDR P35968 1/20 0.49
FLT3 P36888 1/20 0.49
BLK P51451 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122655 1.00 MAPK1 (0.69) MAPK1MTORBAZ1AJAK2JAK1
SCHEMBL4130879 1.00 MAPK1 (0.69) MAPK1MTORBAZ1AJAK2JAK1
SCHEMBL4128864 0.89 ULK1 (0.60) MAPK1JAK2JAK1ULK1KDR
SCHEMBL4128879 0.89 ULK1 (0.60) MAPK1JAK2JAK1ULK1KDR
SCHEMBL4128868 0.89 ULK1 (0.60) MAPK1JAK2JAK1ULK1KDR
SCHEMBL16564610 0.86 SMN1; SMN2 (0.57) MAPK1JAK2JAK1ULK1KDR
SCHEMBL4137873 0.86 SMN1; SMN2 (0.57) MAPK1JAK2JAK1ULK1KDR
SCHEMBL4134588 0.84 MEN1 (0.52) MAPK1JAK2JAK1ULK1MEN1
SCHEMBL4133287 0.84 MEN1 (0.52) MAPK1JAK2JAK1ULK1MEN1
SCHEMBL4134592 0.84 MEN1 (0.52) MAPK1JAK2JAK1ULK1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2040701-B1 AMINOINDAZOLE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2015-03-18 EP claimed
US-8207210-B2 Aminoindazolylurea derivatives MERCK PATENT GMBH (DE) 2012-06-26 US claimed
US-20090253767-A1 AMINOINDAZOLYLUREA DERIVATIVES MERCK PATENT GESELLSCHAFT (DE) 2009-10-08 US claimed
EP-2040701-B1 AMINOINDAZOLE UREA DERIVATIVES MERCK PATENT GMBH (DE) 2015-03-18 EP disclosed
US-8207210-B2 Aminoindazolylurea derivatives MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-8207210-B2 Aminoindazolylurea derivatives MERCK PATENT GMBH (DE) 2012-06-26 US disclosed
US-20090253767-A1 AMINOINDAZOLYLUREA DERIVATIVES MERCK PATENT GESELLSCHAFT (DE) 2009-10-08 US disclosed
US-20090253767-A1 AMINOINDAZOLYLUREA DERIVATIVES MERCK PATENT GESELLSCHAFT (DE) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253767-A1 AMINOINDAZOLYLUREA DERIVATIVES SGK2, SGK1, SGK3 MAPK1 594/4885MTOR 448/4885BAZ1A 4041/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.